Feedback
Settings

Settings

Goto Application

1. WO2021220250 - LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASE

Submit observation
PermaLink
Publication Number WO/2021/220250
Publication Date 04.11.2021
International Application No. PCT/IB2021/053651
International Filing Date 30.04.2021
IPC
A61K 31/4439 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • MINORYX THERAPEUTICS S.L. [ES]/[ES]
  • INSTITUT DE RECERCA DE LA SIDA-CAIXA [ES]/[ES]
  • PEDEMONTE, Marc Martinell [ES]/[ES]
  • PIZCUETA, Maria Pilar [ES]/[ES]
  • SAURA, Anna Vilalta [ES]/[ES]
  • LÓPEZ, Estefania Traver [ES]/[ES]
  • POLI, Sonia Maria [IT]/[CH]
  • USEROS, Nuria Izquierdo [ES]/[ES]
Inventors
  • PEDEMONTE, Marc Martinell
  • PIZCUETA, Maria Pilar
  • SAURA, Anna Vilalta
  • LÓPEZ, Estefania Traver
  • POLI, Sonia Maria
  • USEROS, Nuria Izquierdo
Priority Data
20382356.230.04.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASE
(FR) LERIGLITAZONE POUR LE TRAITEMENT D'UNE INFLAMMATION PULMONAIRE ET D'UNE MALADIE PULMONAIRE INTERSTITIELLE
front page image
Abstract
(EN) The present disclosure provides methods of treating viral-induced inflammatory lung conditions or diseases, acute inflammation of the lung, or interstitial lung disease with 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof, or 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
(FR) La présente invention concerne des méthodes de traitement d'affections ou de maladies pulmonaires inflammatoires induites par un virus, d'une inflammation aiguë du poumon ou de la maladie pulmonaire interstitielle avec la 5-[[4-[2-[5-(1-hydroxyéthyl)pyridin-2-yl]éthoxy]phényl]méthyl]-1,3-thiazolidine-2,4-dione, ou un sel pharmaceutiquement acceptable de celle-ci, ou la 5-[[4-[2-[5-acétylpyridin-2-yl]éthoxy] phényl]méthyl]-1,3-thiazolidine-2,4-dione, ou un sel pharmaceutiquement acceptable de celle-ci.
Latest bibliographic data on file with the International Bureau
# -